Revolution Medicines, Inc. (RVMD) Insider Sells Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) is among the most promising biotech stocks to buy according to hedge funds. On September 24, 2025, General Counsel and Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), Jeff Cislini, offloaded 1,799 shares of common stock, priced at $44.26 per share. This transaction of $79,623 leaves the ownership of Cislini to 50,425 shares of the company’s stock, including 43,910 restricted stock units.

Just recently, Revolution Medicines, Inc. (NASDAQ:RVMD) reported outstanding Phase 1 data for daraxonrasib in metastatic pancreatic cancer, which showed high response and disease control rates. In contrast to the traditional standards, daraxonrasib demonstrated better efficacy and durability, highlighting promising results in both monotherapy and combination with gemcitabine.

What builds the case even stronger is the company’s $2 billion deal with Royalty Pharma, allowing strong funding as Revolution Medicines, Inc. (NASDAQ:RVMD) accelerates to a transforming Phase 3 trial, which has the potential to completely revolutionize PDAC treatments.

Revolution Medicines, Inc. (NASDAQ:RVMD) is a California-based clinical-stage precision oncology company specializing in novel targeted therapies for RAS-addicted cancers. Incorporated in 2014, the company is focused on developing innovative solutions for people suffering from RAS-addicted cancers.

While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.